To commemorate the 35th anniversary of Annals of Oncology, this interview features Prof. Fabrice André, who served as Editor-in-Chief from 2019 to 2024.
Prof. André shares insights into the significant advancements in oncology during his tenure, the journal’s pivotal contributions to precision medicine, and his efforts to enhance the journal’s scientific impact and global reach. He also reflects on memorable publications, the evolving landscape of cancer research, and offers thoughtful guidance to emerging scientists on the broader purpose of research and its impact beyond academic publishing.
How was oncology when you became Editor-in-Chief of Annals of Oncology, and what contributions did the journal make to the field at that time?
When I started, oncology largely followed a 'one-size-fits-all' approach. Annals of Oncology made a significant impact by disseminating research that advanced the field towards a more precise and personalised practice, focusing on the molecular mechanisms of the disease.
What major challenges did you face in your role, and how did you address them?
Honestly, most likely thanks to the excellent job of my predecessors, I didn't encounter any notable challenge during my tenure.
Can you share a memorable moment during your tenure that highlights the journal's impact on oncology?
A highlight for me was the publication of the first study on circulating tumour DNA (ctDNA) for early cancer detection (Liu et al., 2020). It was an emotional milestone, marking Annals of Oncology’s establishment as a prestigious, high-impact journal.
What advice would you give to emerging researchers who wish to publish in Annals of Oncology?
My main advice is that publication should not be the ultimate goal of research. The true aim is to advance the field and help patients, and this is the spark that produces the most impactful, high-quality research. Publishing is merely a tool for sharing knowledge and spreading your findings to a broader audience.